LAZARD ASSET MANAGEMENT LLC - REVANCE THERAPEUTICS INC ownership

REVANCE THERAPEUTICS INC's ticker is and the CUSIP is 761330AB5. A total of 22 filers reported holding REVANCE THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
LAZARD ASSET MANAGEMENT LLC ownership history of REVANCE THERAPEUTICS INC
ValueSharesWeighting
Q2 2023$12,760
-70.8%
12,050,000
-66.1%
0.02%
-71.9%
Q1 2023$43,718
+63.3%
35,500,000
+22.4%
0.06%
+54.1%
Q4 2022$26,767
-99.9%
29,000,000
-11.1%
0.04%
-28.8%
Q3 2022$35,563,000
+60.3%
32,627,000
+19.6%
0.05%
+73.3%
Q2 2022$22,190,000
-15.0%
27,270,000
-1.8%
0.03%0.0%
Q1 2022$26,121,000
-6.2%
27,770,000
-12.0%
0.03%0.0%
Q4 2021$27,858,000
-5.3%
31,545,000
+23.7%
0.03%
-9.1%
Q3 2021$29,411,000
+25.5%
25,500,000
+27.5%
0.03%
+26.9%
Q2 2021$23,433,000
+15.5%
20,000,000
+11.0%
0.03%
+4.0%
Q1 2021$20,283,00018,019,0000.02%
Other shareholders
REVANCE THERAPEUTICS INC shareholders Q3 2021
NameSharesValueWeighting ↓
READYSTATE ASSET MANAGEMENT LP 17,500,000$21,551,2502.00%
CSS LLC/IL 17,325,000$21,353,2881.41%
SSI INVESTMENT MANAGEMENT LLC 7,938,000$9,735,9660.68%
Boussard & Gavaudan Investment Management LLP 5,000$6,146,2120.58%
Context Capital Management, LLC 3,249$4,0010.34%
LINDEN ADVISORS LP 20,000,000$24,645,5860.26%
AVIVA PLC 22,325,000$27,381,6130.12%
DeepCurrents Investment Group LLC 2,384,000$2,931,9800.11%
LAZARD ASSET MANAGEMENT LLC 35,500,000$43,7180.06%
D. E. Shaw & Co., Inc. 34,364,000$42,380,3650.04%
View complete list of REVANCE THERAPEUTICS INC shareholders